Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions



Arash Boroumand Nasr1, Deepika Ponnala1, Someshwar Rao Sagurthi2, Ramesh Kumar Kattamuri3, Vijaya Kumar Marri3, Suresh Gudala1, Chandana Lakkaraju1, Srinivas Bandaru1, 4, Anuraj Nayarisseri5*



1Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Hyderabad 500 016, India; 2Department of Genetics, Osmania University, Hyderabad 500 007, India; 3Government General and Chest Hospital, Gandhi Medical College and Osmania Medical College, Hyderabad - 500 038, India; 4National Institute of Pharmaceutical Education and Research, Hyderabad 500 037, India; 5In silico Research Laboratory, Eminent Biosciences, Indore 452 010, Madhya Pradesh, India


Email; *Corresponding author


Article Type




Received June 08, 2015; Revised June 28, 2015; Accepted June 29, 2015; Published June 30, 2015



Mammalian target of rapamycin (mTOR) is a key regulator of cell growth, proliferation and angiogenesis. mTOR signaling is frequently hyper activated in a broad spectrum of human cancers thereby making it a potential drug target. The current drugs available have been successful in inhibiting the mTOR signaling, nevertheless, show low oral bioavailability and suboptimal solubility. Considering the narrow therapeutic window of the available inhibitors, through computational approaches, the present study pursues to identify a compound with optimal oral bioavailability and better solubility properties in addition ensuing high affinity between FKBP12 and FRB domain of mTOR. Current mTOR inhibitors; Everolimus, Temsirolimus Deforolimus and Echinomycin served as parent molecules for similarity search with a threshold of 95%. The query molecules and respective similar molecules were docked at the binding cleft of FKBP12 protein. Aided by MolDock algorithm, high affinity compounds against FKBP12 were retrieved. Patch Dock supervised protein-protein interactions were established between FRB domain of mTOR and ligand (query and similar) bound and free states of FKBP12. All the similar compounds thus retrieved showed better solubility properties and enabled better complex formation of mTOR and FKBP12. In particular Everolimus similar compound PubChem ID: 57284959 showed appreciable drugs like properties bestowed with better solubility higher oral bioavailability. In addition this compound brought about enhanced interaction between FKBP12 and FRB domain of mTOR. In the study, we report Everolimus similar compound PubChem ID: 57284959 to be potential inhibitor for mTOR pathway which can overcome the affinity and solubility concerns of current mTOR drugs.



mTOR, FRB domain, FKBP12, Solubility, Human oral absorption, virtual screening, Protein-protein interactions.



mTOR: Mammalian Target of Rapamycin; FRB domain: FKBP12-rapamycin associated protein; FKBP12: FK506-binding protein 12; OPLS: Optimized Potentials for Liquid Simulations; Akt: RAC-alpha serine/threonine-protein kinase; PI3K: phosphatidylinositide 3-kinases



Nasr et al. Bioinformation 11(6): 307-315 (2015)

Edited by

P Kangueane






Biomedical Informatics



This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.